Guide
How to Establish a Pharmaceutical or Biologics Manufacturing Facility in the UAE
Published
The short answer
A UAE pharmaceutical or biologics plant needs three separate approvals. The Emirates Drug Establishment (EDE) registers the manufacturer and the product, and its marketing-authorisation service asks for a manufacturer registration certificate that names the intended production line, with MOHAP's Good Manufacturing Practice (GMP) position confirmed alongside. The emirate health authority, either the Dubai Health Authority (DHA) or the Department of Health in Abu Dhabi (DOH), licenses the establishment. The Ministry of Industry and Advanced Technology (MOIAT) licenses the factory after inspecting it. The dosage form and process you plan to run decide the route, because GMP scope, utilities and qualified-person requirements follow from them, not from the trade licence's activity.
The regulatory perimeter: three approvals, not one
A pharmaceutical or biologics manufacturer needs three separate approvals to lawfully operate, and none substitutes for another:
- Product registration and GMP licensing from MOHAP, which governs whether a specific product, in a specific dosage form, made at a named facility, meets pharmaceutical manufacturing standards.
- Health-facility licensing from the emirate authority (DHA in Dubai, DOH in Abu Dhabi), covering the establishment and its professionals.
- An industrial licence from MOIAT, which classifies and permits the manufacturing activity, separate from the commercial trade licence a free zone or mainland authority issues.
A trade licence naming "pharmaceutical manufacturing" as an activity is the easiest of the three to obtain and settles none of the others. Confirm the current scope of each approval with MOHAP, the relevant emirate authority and MOIAT before committing to a site, since the interaction between product registration and facility licensing depends on the dosage form.
What the GMP file has to show
MOHAP's GMP position is built around the facility and the process, not the paperwork around them. Expect to document, at minimum:
- A validated manufacturing process for each dosage form, with batch records that reproduce the same result run after run.
- A quality-management system with named responsibility for release, deviation handling and recall.
- Qualified staff in the roles a GMP facility requires, not a single generalist covering quality, production and regulatory affairs together.
- Facility design and utilities (air handling, water systems, cleanrooms where biologics or sterile production is involved) built to the process, not retrofitted to a leased shell afterwards.
Biologics and sterile production carry a materially higher validation and containment burden than solid-dose finished products, which is why the launch model (finished-dose, biologics or sterile, bulk and intermediate, or contract manufacturing under another brand owner's licence) has to be fixed before the facility is designed.
How money moves, and what a bank looks at
Pharmaceutical manufacturing is capital-intensive before it is revenue-generating: facility fit-out, validated equipment, qualified staff and product registration all come ahead of the first sale. A bank assessing account readiness asks where that capital came from, what it has already funded, and which contracts (a brand owner's manufacturing agreement, a distributor commitment, a technology-transfer licence) justify the scale being built. An unexplained capital inflow funding a regulated facility is a question a bank answers before onboarding, not after.
Prepare a source-of-funds record alongside the facility plan; where capital includes external investors or fees from abroad, build that evidence through source-of-wealth and funds support early. A technology-transfer or local-manufacturing agreement should be a signed, current document the bank can read, not a described intention.
Ownership, substance and the roles that must be filled
A pharmaceutical facility needs named, accountable people in roles a regulator asks to meet directly: a responsible or qualified person over GMP compliance, a quality lead who can authorise or block a batch release, and someone accountable for safety and recall decisions. A licence held by an absent shareholder, backed by staff with no documented authority, reads as a facility without substance to the health authority and a bank alike.
Where ownership is layered (a foreign manufacturer's UAE subsidiary, a joint venture with a local partner, or a brand owner licensing production to a UAE contract manufacturer), document the chain from the people who hold the equity to the people the regulator and the bank actually call. Structure that chain as regulated and complex ownership from the outset rather than resolving it once a bank or an inspector asks who is really in control.
What commonly goes wrong
- Filing for a trade licence before confirming the GMP and facility-licensing position with MOHAP and the emirate authority.
- Leasing or fitting out a site before the process and utilities it needs are defined, then retrofitting cleanrooms into a shell built for something else.
- Treating a technology-transfer conversation as a signed agreement before it is one.
- Under-resourcing the quality and qualified-person roles a GMP facility needs, leaving one person accountable for functions that should be separated.
- Comparing formation cost across jurisdictions before confirming the GMP, facility-licensing and industrial-licence position is even the same between them.
Most of these share one root cause: the facility and the equipment get ordered against an assumed regulatory position rather than a confirmed one, and the correction (once walls and long-lead equipment are in place) is far more expensive than getting the sequence right at the start.
From licence to operating facility
Securing the three approvals is the start, not the finish. A qualified workforce needs visas tied to the licensed entity and, often, professional registration with the health authority. Premises must match what MOHAP and the emirate authority approved, because a change of site, an added production line or a new dosage form typically reopens the facility approval rather than being a simple notification. Corporate tax and VAT apply as usual, and GMP licences, product registrations and the industrial licence each carry their own renewal and inspection schedule, independent of the trade licence's own date.
